Background: While early recurrent MI (re MI) after thrombolytic therapy has been associated with higher short-term mortality in acute MI, its relationship to long-term mortality has not been explored. We hypothesized that re MI would be associated with higher mortality at both 30 days and 2 years due to the association of reMI with lower EF, more CHF, and more SCD/CHF death, Methods: 30 day mortality was ascertained in the InTIME-II trial and the TIMI 4, 9A, 9B, and 10B acute MI triels. 5122 patients had followup <1 yr, 14379 patients had data from 1 yr to <2 years, and 598 had >=2 years, but all data after 2 yrs was censored at 2 yrs. Results: The frequency of re MI dudng the index hospitalization was 4.16% (836/20101) in the five trials. Mortality by 30 days was increased in patients who experienced re MI during the index hospitalization (16.4%, 137/836 vs 6.17%, 1188/19260, p<0.001). Long-term mortality remained higher in patients sustaining re MI, even after adjusting for age, anterior MI, pulse on admission, and gender (Hazard ratio=2.07, p<0.001, Figure) . However, in an analysis restricted to patients who survived the index hospitalization, long-term mortality was not significantly higher in patients who had an early reinfarction (4.38%, 31/707 vs 3.76%, 685/18206, p=NS).
Conclusion:
Early re MI is associated with increased mortality at 2 years. However, most deaths occur early, and the dsk of additional deaths between the index hospitalization and 2 years did not appear to be increased. Background: Combination therapy with reduced dose plasminogen activator and full dose platelet glycoprotein lib/Ilia receptor blockade significantly reduces recurrent ischemia after myocardial infarction. This clinical benefit may result from coronary artery passivation, defined as the inability to recruit new platalets to the site of endothelial disruption. We sought to determine whether combination therapy induces rapid coronary artery passivation following successful thrombolysis. Methods: Using scanning electron microscopy (SEM), we examined platelet and fibdn accumulation in a canine model of acute myocardial infamtion. Occlusive left anterior descending coronary artery thrombosis was produced after endothelial disruption in the presence of a superimposed >90% distal stenosis. Animals were treated with either Eptifibatide (Ep) alone (n=11) or Ep + rt-PA (n=11). Ep was infused at a dose of 0.5 mg/kg + 6 p.g/kg/min IV for 90 min and rt-PA was given at a reduced dose of 0.45 mg/kg IV. All animals received intravenous heparin (to maintain ACT > 250 sec) and aspirin (10 mg/kg). The coronary pathology was examined at termination of Ep (T1) in 6 dogs from each treatment group and 2 hours after termination of Ep (T2) In the ASSENT-3 trial the co-administration of abciximab (ABC) and half-dose tenecteplase was associated with a significant increase in non-cerebral bleeding complications when compared with full-dose tenecteplase and ACC/AHA recommended doses of unfractionatad heparin (UFH). A non-significant trend towards more bleeding complications was also observed with the combination of full-dose tenecteplase and sustained SC administration of enoxaparin (ENOX). We analyzed the incidence of spontaneous and puncture-related bleeding complications in the 3 treatment groups of ASSENT-3 (table) . Conclusion: When compared with unfractionated heperin, abciximab but not enoxaparin increased the risk of spontaneous bleeding complications when given in association with tenecteplase. Neither abciximab nor enoxaparin induced more bleadings of the arterial puncture site. 
